{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:06Z","timestamp":1791518706836,"version":"4.3.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Farma SpA"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      DESCRIBE Italy is an observational, retrospective, real-world study evaluating dabrafenib plus trametinib in 499 patients with BRAF\n                      <jats:sup>V600<\/jats:sup>\n                      -mutant stage III unresectable or stage IV melanoma from various sites across Italy. Here, we analyzed the clinical outcomes for the subgroup of patients receiving first-line treatment and presenting with BM at diagnosis and assessed the impact of predictive factors such as LDH levels and the presence of other metastases on median progression-free survival (mPFS).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Overall, 325 evaluable patients were on first-line therapy and are the focus of this analysis; of these, 76 patients (23.4%) had BM at baseline. mPFS was lower for patients with BM at baseline compared with overall patients (8.7 months vs 9.3 months, respectively). Patients with BM at diagnosis and LDH &gt;ULN had a considerably shorter mPFS compared with patients with LDH \u2a7dULN (5.3 months vs 9.9 months, respectively). mPFS was noticeably longer for patients with cerebral metastases only compared with patients with cerebral and other metastases (15.0 months vs 8.7 months, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Dabrafenib plus trametinib showed effectiveness in a real-world population of patients with advanced BRAF\n                      <jats:sup>V600<\/jats:sup>\n                      -mutated melanoma and BM at baseline, supporting its use in this population with poor outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916231179251","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T05:45:16Z","timestamp":1688708716000},"page":"537-545","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes in patients with\n                    <i>BRAF<\/i>\n                    <sup>V600<\/sup>\n                    \u2013mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-7377","authenticated-orcid":false,"given":"Massimo","family":"Aglietta","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Torino, Torino, Italy"},{"name":"Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[{"name":"Melanoma Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Veneto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fava","sequence":"additional","affiliation":[{"name":"Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Piemonte, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Guidoboni","sequence":"additional","affiliation":[{"name":"Immunotherapy - Cell Therapy and Biobank, IRCCS-IRST, Meldola (FC), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Depenni","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, University Hospital of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Minisini","sequence":"additional","affiliation":[{"name":"Department of Oncology, Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[{"name":"Department of Oncology, ASST Spedali Civili, Brescia, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"UOC Oncologia Medica Aoup Paolo Giaccone, Palermo, Sicilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Banzi","sequence":"additional","affiliation":[{"name":"Oncology Unit, Presidio Ospedaliero Arcispedale Santa Maria Nuova AUSL di Reggio Emilia \u2013 IRCCS, Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[{"name":"Presidio Ospedaliero S. Chiara - Az. Ospedaliero Universitaria Pisana, Pisa, Toscana, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Gueli","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASST Sette Laghi, Circolo Hospital and Macchi Foundation, Varese, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ferraresi","sequence":"additional","affiliation":[{"name":"Sarcomas and Rare Tumors Unit, IRCCS - Regina Elena National Cancer Institute, Rome, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tucci","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Clinical Oncology, University of Bari, \u201cAldo Moro,\u201d Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[{"name":"Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Guida","sequence":"additional","affiliation":[{"name":"Rare Tumors and Melanoma Unit, IRCCS Istituto dei Tumori Giovanni Paolo II, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Gioia","family":"Marcon","sequence":"additional","affiliation":[{"name":"Novartis Farma S.p.A, Origgio, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[{"name":"Oncology Division, Policlinico San Martino IRCCS, Genova, Liguria, Italy"},{"name":"Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"bibr1-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.11.014"},{"key":"bibr2-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11125.x"},{"key":"bibr3-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27616"},{"key":"bibr4-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00109-1"},{"key":"bibr5-03008916231179251","unstructured":"AIOM-CCM-AIRTUM. I numeri del cancro in Italia 2020, http:\/\/www.registri-tumori.it\/cms\/"},{"key":"bibr6-03008916231179251","first-page":"864680","volume":"2012","author":"Crocetti E","year":"2012","journal-title":"ISRN Oncol"},{"key":"bibr7-03008916231179251","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph120809102"},{"key":"bibr8-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1108494"},{"key":"bibr9-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25634"},{"key":"bibr10-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.03.003"},{"key":"bibr11-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4374-x"},{"key":"bibr12-03008916231179251","volume":"100","author":"Xu J","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"bibr13-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000520"},{"key":"bibr14-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.034"},{"key":"bibr15-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"bibr16-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26724"},{"key":"bibr17-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"bibr18-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406037"},{"key":"bibr19-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690"},{"key":"bibr20-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059"},{"key":"bibr21-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000654"},{"key":"bibr22-03008916231179251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102466"},{"key":"bibr23-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00850-1"},{"key":"bibr24-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00850-1"},{"key":"bibr25-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.07.016"},{"key":"bibr26-03008916231179251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112529"},{"key":"bibr27-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.033"},{"key":"bibr28-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"bibr29-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25631"},{"key":"bibr30-03008916231179251","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235763"},{"key":"bibr31-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.6018"},{"key":"bibr32-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"bibr33-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000333"},{"key":"bibr34-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30578-2"},{"key":"bibr35-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000816"},{"key":"bibr36-03008916231179251","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1731942"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916231179251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916231179251","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916231179251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:42:55Z","timestamp":1777660975000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916231179251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1177\/03008916231179251"],"URL":"https:\/\/doi.org\/10.1177\/03008916231179251","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}